Current Report Filing (8-k)
13 Ottobre 2021 - 4:02PM
Edgar (US Regulatory)
0001335105
false
false
0001335105
2021-10-08
2021-10-08
0001335105
us-gaap:CommonStockMember
2021-10-08
2021-10-08
0001335105
LIXT:WarrantToPurchaseCommonStockMember
2021-10-08
2021-10-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 8, 2021
LIXTE
BIOTECHNOLOGY HOLDINGS, INC.
delaware
|
|
001-39717
|
|
20-2903526
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
680
East Colorado Boulevard, Suite 180
Pasadena,
California
91101
(Address
of principal executive offices)
(631)
830-7092
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (See General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
LIXT
|
|
The
Nasdaq Stock Market LLC
|
Warrant
to Purchase Common Stock
|
|
LIXTW
|
|
The
Nasdaq Stock Market LLC
|
Item
1.01 Entry into a Material Definitive Agreement.
Development
and Collaboration Agreement
On
October 8, 2021, Lixte Biotechnology Holdings, Inc. (the “Company”) entered into a Development Collaboration Agreement with
the Netherlands Cancer Institute, Amsterdam (NKI), one of the world’s leading comprehensive cancer centers, and Oncode Institute,
Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially
LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified
combinations.
Item
8.01 Other Events.
On
October 13, 2021, the Company issued a press release with respect to its entry into the Development Collaboration Agreement.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
The
Company is filing as part of this report the exhibits listed on the accompanying Index to Exhibits, which information is incorporated
herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
|
|
|
|
Date:
October 13, 2021
|
By:
|
/s/
JOHN S. KOVACH
|
|
|
John S. Kovach, President and Chief Executive Officer
|
INDEX
TO EXHIBITS
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024